Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?

Kerri A. Johannson, Irina Strâmbu, Claudia Ravaglia, Jan C. Grutters, Claudia Valenzuela, Nesrin Mogulkoc, Fabrizio Luppi, Luca Richeldi, Athol U. Wells*, Carlo Vancheri, Michael Kreuter, Erice ILD Working Group

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

70 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF) is a progressive parenchymal lung disease of complex cause. Gastro-oesophageal reflux (GER) and microaspiration have been proposed as risk factors for the development and progression of IPF, but robust definitive data are few. A recent international guideline conditionally recommended the use of antacid therapy (proton pump inhibitors or histamine-2-receptor antagonists) for patients with IPF, in the absence of oesophageal reflux or symptoms. In this Position Paper, we summarise the literature addressing the association between GER and IPF, and also identify future research priorities that could clarify this issue. We shed light on the process through which the guideline recommendation was achieved and aim to contextualise the recommendation for providers caring for patients with IPF.

Original languageEnglish
Pages (from-to)591-598
Number of pages8
JournalThe Lancet Respiratory Medicine
Volume5
Issue number7
DOIs
Publication statusPublished - Jul 2017

Bibliographical note

Publisher Copyright:
© 2017 Elsevier Ltd

Fingerprint

Dive into the research topics of 'Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?'. Together they form a unique fingerprint.

Cite this